en · de · es · fr · pt
cardarine-notes.peptides6908.com › Info › Mechanism And Research Context — Worked Examples

Mechanism And Research Context — Worked Examples

By Editorial Desk · published 2025-10-01 · last reviewed 2025-10-25 · Info

This is a working overview of PPARδ, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2025-10-25. Anything still debated is marked as such rather than presented as settled.

Mechanism and Research Context

In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.

GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.

Background and Regulatory Status

Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.

Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.

Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.

Cardarine at a glance

PropertyValueNotes
SolubilitySoluble in dimethyl sulfoxide and some organic solvents; practically insoluble in waterSolvent choice affects laboratory handling
Typical storage-20 °C, desiccated, protected from lightCommon condition for research samples
Analytical methodLiquid chromatography–tandem mass spectrometry (LC-MS/MS)Used for identification and quantification in biological or product samples
Common synonymsGW501516, GW-501516, GSK-516, EndurobolNames found in research and anti-doping literature
Regulatory statusUnapproved therapeutic; prohibited in competitive sportStatus can vary by country and context

Preclinical Findings and Safety Signals

Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.

Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.

Related pages on this site

Regulation and Detection

Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.

Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.

Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.

Cardarine Identity and Mechanism

Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.

At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.

Further detail

=== Differential diagnosis === 6-phosphogluconate dehydrogenase (6PGD) deficiency has similar symptoms and is often mistaken for G6PD deficiency, as the affected enzyme is within the same pathway; however, these diseases are not linked and can be found within the same person.

Most of the Afghan population was already going hungry at the time of the attacks. In the aftermath of the attacks, tens of thousands of people attempted to flee Afghanistan due to the possibility of military retaliation by the U.S. and Pakistan, already home to many Afghan refugees from previous conflicts, closed its border with Afghanistan on September 17, 2001. Thousands of Afghans also fled to the frontier with Tajikistan but were denied entry. The Taliban leaders in Afghanistan pleaded against military action, saying "We appeal to the United States not to put Afghanistan into more misery because our people have suffered so much", referring to two decades of conflict and the humanitarian crisis attached to it. All United Nations expatriates had left Afghanistan after the attacks and no national or international aid workers were at their post. Workers were instead preparing in bordering countries like Pakistan, China and Uzbekistan to prevent a potential "humanitarian catastrophe", amid a critically low food stock for the Afghan population. The World Food Programme stopped importing wheat to Afghanistan on September 12 due to security risks.

During this period, the average EBITDA/sales and EBIT/sales ratios of representative companies were 15% and 71⁄2%, respectively; during the boom, they were 20% and 10–13% respectively and, during the bust, they were 10% and 5% respectively. The differences within these ranges reflects the volatility of the industry's profitability. All in all, the average Western fine-chemical firms have been making a return below the cost of capital — they are not reinvestment grade.

=== Pharmacokinetics === Salvinorin A is effectively deactivated by the gastrointestinal system, so alternative routes of administration must be used for better absorption. It is absorbed by oral mucosa. It has a half-life of around 8 minutes in non-human primates.

Sources: en.wikipedia.org

Background from the literature

Using Mendeleev's nomenclature for unnamed and undiscovered elements, copernicium should be known as eka-mercury. In 1979, IUPAC published recommendations according to which the element was to be called ununbium (with the corresponding symbol of Uub), a systematic element name as a placeholder, until the element was discovered (and the discovery then confirmed) and a permanent name was decided on. Although widely used in the chemical community on all levels, from chemistry classrooms to advanced textbooks, the recommendations were mostly ignored among scientists in the field, who either called it "element 112", with the symbol of E112, (112), or even simply 112. After acknowledging the GSI team's discovery, the IUPAC asked them to suggest a permanent name for element 112. On 14 July 2009, they proposed copernicium with the element symbol Cp, after Nicolaus Copernicus "to honor an outstanding scientist, who changed our view of the world". During the standard six-month discussion period among the scientific community about the naming, it was pointed out that the symbol Cp was previously associated with the name cassiopeium (cassiopium), now known as lutetium (Lu). Moreover, Cp is frequently used today to mean the cyclopentadienyl ligand (C5H5). Primarily because cassiopeium (Cp) was (until 1949) accepted by IUPAC as an alternative allowed name for lutetium, the IUPAC disallowed the use of Cp as a future symbol, prompting the GSI team to put forward the symbol Cn as an alternative.

Mast cells play a key role in the inflammatory process. Histamine dilates post-capillary venules, activates the endothelium, and increases blood vessel permeability. This leads to local edema (swelling), warmth, redness, and the attraction of other inflammatory cells to the site of release. It also depolarizes nerve endings (leading to itching or pain). Cutaneous signs of histamine release are the "flare and wheal" reaction. The bump and redness immediately following a mosquito bite are a good example of this reaction, which occurs seconds after challenge of the mast cell by an allergen.

== Properties == Protolichesterinic acid is a member of the class of chemicals known as lactone fatty acids, a group that includes lichesterinic acid, alloprotolichesterinic acid, nephromopsinic acid, and nephrosterinic acid. In its purified form, protolichesterinic acid is a crystalline solid that forms lustrous plates when recrystallized from benzene or acetic acid at temperatures below 50 °C (122 °F). It has a melting point of 107.5 °C (225.5 °F). The compound exists in both enantiomeric forms, with the (+)-enantiomer showing an optical rotation of [α]D +12° in chloroform and the (-)-enantiomer showing [α]D -12° in chloroform. In ultraviolet–visible spectroscopy, it shows maximum absorption at 218 nm in methanol. Its infrared spectrum (KBr) shows characteristic peaks including those corresponding to carboxylic acid (3450 cm−1), alkene (3050 cm−1), and carbonyl (1720 cm−1) functionalities. Nuclear magnetic resonance spectroscopy confirms its structure, with distinctive signals in the 1H NMR spectrum including the terminal methyl group at δ 0.68 ppm and alkene protons at δ 6.03 and 6.39 ppm. The 13C NMR spectrum shows key resonances for the carboxylic acid (174.4 ppm), alkene (132.6 and 125.9 ppm), and lactone carbonyl (168.2 ppm) carbons.

Sources: en.wikipedia.org

Frequently asked questions

How does cardarine work in the body?

It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.

Is cardarine a steroid?

No. It is not an anabolic-androgenic steroid; it is a synthetic PPARδ agonist. Because it is banned in sport, it is sometimes grouped with doping agents even though its chemical class differs from steroids.

What do human studies show?

Human data are limited and development was discontinued, so major effects and long-term risks are not well characterized. Some early studies examined metabolic markers, but they do not provide a basis for unsupervised use.

Is cardarine approved for human use?

No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.

Network